Rallybio Corporation has announced the sale of its interest in the REV102 program to Recursion Pharmaceuticals, a move anticipated to extend Rallybio's cash runway to mid-2027. The deal, valued at up to $25 million, includes an upfront equity payment of $7.5 million and additional milestone payments. The REV102 program, focused on developing an ENPP1 inhibitor for treating hypophosphatasia $(HPP)$, originated from a joint venture between the two companies. Rallybio's CEO, Stephen Uden, expressed enthusiasm for the program's progression, highlighting the collaboration's success in advancing a potential oral disease-modifying treatment for HPP.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250707702845) on July 08, 2025, and is solely responsible for the information contained therein.